STOCK TITAN

Revvity, Inc. - RVTY STOCK NEWS

Welcome to our dedicated page for Revvity news (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.

Revvity, Inc. (RVTY) is a leading company dedicated to enhancing human and environmental health. The company collaborates with scientists, clinicians, and government agencies to develop more effective diagnostics and therapies. Additionally, Revvity ensures the safety of our food and air by detecting contaminants that could harm the environment and public health.

Revvity operates under two main segments: Diagnostics and Discovery & Analytical Solutions. The Diagnostics segment focuses on areas such as immunodiagnostics, reproductive health, and applied genomics. This division provides crucial tools and tests for genetic screening and various health diagnostics. Meanwhile, the Discovery & Analytical Solutions segment addresses life science research and industrial applications, offering products and services for environmental and food analysis, as well as informatics and enterprise software solutions.

In recent achievements, Revvity has been at the forefront of developing innovative solutions that transform raw data into actionable insights, thus improving public health and environmental safety. The company’s systems are instrumental in rapidly detecting both known and unknown contaminants in food, water, and air. They also play a critical role in ensuring compliance with health and safety standards.

Revvity's partnerships span across the pharmaceutical, biomedical, chemical, environmental, and industrial markets, making it a versatile player in multiple sectors. The company’s commitment to quality and innovation has led to significant advancements in research and diagnostics, making it a key contributor to global health and safety.

Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) announces Q4 2023 financial results, including a revenue decline of -7% and -4% in organic revenue. Full year 2023 adjusted earnings per share expected to meet or exceed guidance. Prahlad Singh to present at J.P. Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) will present at the 42nd annual J.P. Morgan Healthcare Conference to provide an update on the Company and its strategic priorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
conferences
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) to Present at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
conferences
Rhea-AI Summary
Revvity, Inc. reported Q3 2023 financial results with $671 million in revenue, representing a 6% decrease. GAAP EPS was $0.08, compared to $0.67 in the same period last year. Adjusted EPS from continuing operations was $1.18. The company updated its full year 2023 guidance with a forecasted revenue of $2.72-$2.74 billion and adjusted EPS of $4.53-$4.57.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
-
Rhea-AI Summary
Revvity (NYSE: RVTY) declares regular quarterly dividend of $0.07 per share of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
dividends
-
News
Rhea-AI Summary
Revvity, Inc. unveils its inaugural 2023 ESG Report, highlighting its commitment to sustainability and transparency. Key goals include reducing greenhouse gas emissions by 50% by 2033, achieving net carbon neutrality by 2040, and maintaining greater than 40% female representation in leadership positions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) to release Q3 2023 financial results on October 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
-
Rhea-AI Summary
Revvity launches Pin-point base editing reagents, providing access to advanced gene editing technique. Can enhance drug development and streamline cell therapy research. Pin-point platform used in clinical settings. Reagents include mRNAs for nCas9 and rat APOBEC, as well as three guide RNAs. Revvity aims to democratize access to base editing. Entered non-exclusive license agreement with AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
-
Rhea-AI Summary
Revvity debuts enhanced imaging portfolio with new systems, including IVIS Spectrum 2, IVIS SpectrumCT 2, Quantum GX3 microCT, and Vega ultrasound system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) to present at upcoming healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences

FAQ

What is the current stock price of Revvity (RVTY)?

The current stock price of Revvity (RVTY) is $112.56 as of December 20, 2024.

What is the market cap of Revvity (RVTY)?

The market cap of Revvity (RVTY) is approximately 13.6B.

What does Revvity, Inc. specialize in?

Revvity specializes in improving human and environmental health through diagnostics, therapies, and contaminant detection.

What are the main segments of Revvity?

Revvity operates under two main segments: Diagnostics and Discovery & Analytical Solutions.

What services does Revvity provide?

Revvity provides instruments, tests, services, and software solutions for pharmaceutical, biomedical, chemical, environmental, and industrial markets.

How does Revvity contribute to environmental health?

Revvity helps detect contaminants in food, water, and air, ensuring compliance with health and safety standards.

What recent achievements has Revvity made?

Revvity has developed innovative solutions that transform data into actionable insights, improving public health and safety.

What industries does Revvity serve?

Revvity serves pharmaceutical, biomedical, chemical, environmental, and general industrial markets.

What are some key products offered by Revvity?

Key products include genetic screening tools, environmental analytical instruments, and informatics software.

How does Revvity support life science research?

Revvity provides life science research instrumentation and diagnostic lab services to advance health and scientific understanding.

Who are Revvity's primary partners?

Revvity partners with scientists, clinicians, government agencies, and industries to improve diagnostics and environmental health.

How does Revvity ensure the safety of food and air?

Revvity uses advanced systems to detect contaminants and monitor the quality of food and air, ensuring compliance with safety standards.

Revvity, Inc.

NYSE:RVTY

RVTY Rankings

RVTY Stock Data

13.62B
121.35M
0.29%
92.08%
3.36%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States of America
WALTHAM